Neonatal administration of Lactiplantibacillus plantarum ATCC 202195 with or without fructooligosaccharide in Bangladesh: a placebo-controlled randomized trial.
Lisa G Pell, Huma Qamar, Diego G Bassani, Cole Heasley, Celine Funk, Chun-Yuan Chen, Jakaria Shawon, Karen M O'Callaghan, Eleanor Pullenayegum, Davidson H Hamer, Rashidul Haque, Mamun Kabir, Tahmeed Ahmed, Ciobha O'Kelly, Md Iqbal Hossain, Afreen Z Khan, Miranda G Loutet, Mohammad Shahidul Islam, Shaun K Morris, Prakesh S Shah, Philip M Sherman, Shamima Sultana, Abdullah Al Mahmud, Samir K Saha, Shafiqul A Sarker, Daniel E Roth
{"title":"Neonatal administration of <i>Lactiplantibacillus plantarum</i> ATCC 202195 with or without fructooligosaccharide in Bangladesh: a placebo-controlled randomized trial.","authors":"Lisa G Pell, Huma Qamar, Diego G Bassani, Cole Heasley, Celine Funk, Chun-Yuan Chen, Jakaria Shawon, Karen M O'Callaghan, Eleanor Pullenayegum, Davidson H Hamer, Rashidul Haque, Mamun Kabir, Tahmeed Ahmed, Ciobha O'Kelly, Md Iqbal Hossain, Afreen Z Khan, Miranda G Loutet, Mohammad Shahidul Islam, Shaun K Morris, Prakesh S Shah, Philip M Sherman, Shamima Sultana, Abdullah Al Mahmud, Samir K Saha, Shafiqul A Sarker, Daniel E Roth","doi":"10.1128/msphere.01032-24","DOIUrl":null,"url":null,"abstract":"<p><p><i>Lactiplantibacillus plantarum</i> ATCC 202195 (LP202195) plus fructooligosaccharide (FOS) for 7 days was previously shown to colonize the infant intestine up to 6 months of age and reduced sepsis rates among young infants in rural India. In a phase 2 randomized controlled trial in Dhaka, Bangladesh (<i>N</i> = 519), neonatal administration of LP202195 for 1 or 7 days, with or without FOS, increased LP202195 stool abundance from 14 to 60 days of age, versus placebo. Abundance progressively declined in the post-administration period and did not persist beyond 2 months of age. FOS did not affect LP202195 abundance or its duration of persistence. All regimens were well-tolerated and safe. The absence of LP202195 colonization was inconsistent with results from a prior trial. Additional large-scale trials of LP202195 ± FOS are needed to establish its efficacy in infants who do not become LP202195-colonized.</p><p><strong>Importance: </strong>Among infants born in Dhaka, Bangladesh, a 7-day regimen of <i>Lactiplantibacillus plantarum</i> ATCC 202195 (LP202195) plus fructooligosaccharide (FOS) did not colonize the infant gastrointestinal (GI) tract. The absence of colonization is inconsistent with a prior study of the same synbiotic regimen in India, in which LP202195 was shown to persist in the infant GI tract for up to 6 months. Sustained LP202195 colonization was thought to be required for the probiotic to impart its beneficial impact on newborn sepsis. Therefore, additional trials are warranted to confirm the previously observed effects of LP202195 on infant clinical outcomes in the absence of LP202195 colonization. Moreover, since regimens of LP202195 that did not include FOS were indistinguishable from the synbiotic in terms of colonization, safety, and tolerability, future trials should assess the role of FOS for clinical efficacy; removing FOS would reduce costs, an important consideration for scale-up.</p><p><strong>Clinical trials: </strong>This study has been registered at ClinicalTrials.gov as NCT05180201.</p>","PeriodicalId":19052,"journal":{"name":"mSphere","volume":" ","pages":"e0103224"},"PeriodicalIF":3.7000,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"mSphere","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1128/msphere.01032-24","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Lactiplantibacillus plantarum ATCC 202195 (LP202195) plus fructooligosaccharide (FOS) for 7 days was previously shown to colonize the infant intestine up to 6 months of age and reduced sepsis rates among young infants in rural India. In a phase 2 randomized controlled trial in Dhaka, Bangladesh (N = 519), neonatal administration of LP202195 for 1 or 7 days, with or without FOS, increased LP202195 stool abundance from 14 to 60 days of age, versus placebo. Abundance progressively declined in the post-administration period and did not persist beyond 2 months of age. FOS did not affect LP202195 abundance or its duration of persistence. All regimens were well-tolerated and safe. The absence of LP202195 colonization was inconsistent with results from a prior trial. Additional large-scale trials of LP202195 ± FOS are needed to establish its efficacy in infants who do not become LP202195-colonized.
Importance: Among infants born in Dhaka, Bangladesh, a 7-day regimen of Lactiplantibacillus plantarum ATCC 202195 (LP202195) plus fructooligosaccharide (FOS) did not colonize the infant gastrointestinal (GI) tract. The absence of colonization is inconsistent with a prior study of the same synbiotic regimen in India, in which LP202195 was shown to persist in the infant GI tract for up to 6 months. Sustained LP202195 colonization was thought to be required for the probiotic to impart its beneficial impact on newborn sepsis. Therefore, additional trials are warranted to confirm the previously observed effects of LP202195 on infant clinical outcomes in the absence of LP202195 colonization. Moreover, since regimens of LP202195 that did not include FOS were indistinguishable from the synbiotic in terms of colonization, safety, and tolerability, future trials should assess the role of FOS for clinical efficacy; removing FOS would reduce costs, an important consideration for scale-up.
Clinical trials: This study has been registered at ClinicalTrials.gov as NCT05180201.
期刊介绍：
mSphere™ is a multi-disciplinary open-access journal that will focus on rapid publication of fundamental contributions to our understanding of microbiology. Its scope will reflect the immense range of fields within the microbial sciences, creating new opportunities for researchers to share findings that are transforming our understanding of human health and disease, ecosystems, neuroscience, agriculture, energy production, climate change, evolution, biogeochemical cycling, and food and drug production. Submissions will be encouraged of all high-quality work that makes fundamental contributions to our understanding of microbiology. mSphere™ will provide streamlined decisions, while carrying on ASM''s tradition for rigorous peer review.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
